Associations of Menstrual Cycle Characteristics Across the Reproductive Life Span and Lifestyle Factors With Risk of Type 2 Diabetes | Lifestyle Behaviors | JAMA Network Open | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.153.100.128. Please contact the publisher to request reinstatement.
1.
International Diabetes Federation. IDF diabetes atlas: 9th edition 2019. Accessed August 1, 2019. http://www.diabetesatlas.org
2.
International Diabetes Federation. IDF Diabetes Atlas. 8th ed. International Diabetes Federation; 2018.
3.
Real  FG, Svanes  C, Omenaas  ER,  et al.  Menstrual irregularity and asthma and lung function.   J Allergy Clin Immunol. 2007;120(3):557-564. doi:10.1016/j.jaci.2007.04.041 PubMedGoogle Scholar
4.
Escobar-Morreale  HF.  Reproductive endocrinology: menstrual dysfunction—a proxy for insulin resistance in PCOS?   Nat Rev Endocrinol. 2014;10(1):10-11. doi:10.1038/nrendo.2013.232 PubMedGoogle Scholar
5.
Wlazlo  N, van Greevenbroek  MM, Ferreira  I,  et al.  Iron metabolism is associated with adipocyte insulin resistance and plasma adiponectin: the Cohort on Diabetes and Atherosclerosis Maastricht (CODAM) study.   Diabetes Care. 2013;36(2):309-315. doi:10.2337/dc12-0505 PubMedGoogle Scholar
6.
Cooper  GS, Ephross  SA, Sandler  DP.  Menstrual patterns and risk of adult-onset diabetes mellitus.   J Clin Epidemiol. 2000;53(11):1170-1173. doi:10.1016/S0895-4356(00)00240-7 PubMedGoogle Scholar
7.
LeBlanc  ES, Kapphahn  K, Hedlin  H,  et al.  Reproductive history and risk of type 2 diabetes mellitus in postmenopausal women: findings from the Women’s Health Initiative.   Menopause. 2017;24(1):64-72. doi:10.1097/GME.0000000000000714 PubMedGoogle Scholar
8.
Yang  A, Liu  S, Cheng  N,  et al.  Reproductive factors and risk of type 2 diabetes in an occupational cohort of Chinese women.   J Diabetes Complications. 2016;30(7):1217-1222. doi:10.1016/j.jdiacomp.2016.06.011 PubMedGoogle Scholar
9.
Solomon  CG, Hu  FB, Dunaif  A,  et al.  Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus.   JAMA. 2001;286(19):2421-2426. doi:10.1001/jama.286.19.2421 PubMedGoogle Scholar
10.
Ardisson Korat  AV, Willett  WC, Hu  FB.  Diet, lifestyle, and genetic risk factors for type 2 diabetes: a review from the Nurses’ Health Study, Nurses’ Health Study 2, and Health Professionals’ Follow-up Study.   Curr Nutr Rep. 2014;3(4):345-354. doi:10.1007/s13668-014-0103-5 PubMedGoogle Scholar
11.
Bao  Y, Bertoia  ML, Lenart  EB,  et al.  Origin, methods, and evolution of the three Nurses’ Health Studies.   Am J Public Health. 2016;106(9):1573-1581. doi:10.2105/AJPH.2016.303338 PubMedGoogle Scholar
12.
Jukic  AM, Weinberg  CR, Wilcox  AJ, McConnaughey  DR, Hornsby  P, Baird  DD.  Accuracy of reporting of menstrual cycle length.   Am J Epidemiol. 2008;167(1):25-33. doi:10.1093/aje/kwm265 PubMedGoogle Scholar
13.
Solomon  CG, Hu  FB, Dunaif  A,  et al.  Menstrual cycle irregularity and risk for future cardiovascular disease.   J Clin Endocrinol Metab. 2002;87(5):2013-2017. doi:10.1210/jcem.87.5.8471 PubMedGoogle Scholar
14.
National Diabetes Data Group.  Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance.   Diabetes. 1979;28(12):1039-1057. doi:10.2337/diab.28.12.1039 PubMedGoogle Scholar
15.
 Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.   Diabetes Care. 1997;20(7):1183-1197. doi:10.2337/diacare.20.7.1183 PubMedGoogle Scholar
16.
Manson  JE, Rimm  EB, Stampfer  MJ,  et al.  Physical activity and incidence of non–insulin-dependent diabetes mellitus in women.   Lancet. 1991;338(8770):774-778. doi:10.1016/0140-6736(91)90664-B PubMedGoogle Scholar
17.
Field  AE, Coakley  EH, Must  A,  et al.  Impact of overweight on the risk of developing common chronic diseases during a 10-year period.   Arch Intern Med. 2001;161(13):1581-1586. doi:10.1001/archinte.161.13.1581 PubMedGoogle Scholar
18.
Shan  Z, Li  Y, Zong  G,  et al.  Rotating night shift work and adherence to unhealthy lifestyle in predicting risk of type 2 diabetes: results from two large US cohorts of female nurses.   BMJ. 2018;363:k4641. doi:10.1136/bmj.k4641 PubMedGoogle Scholar
19.
 Physical Activity Guidelines Advisory Committee report, 2008: to the Secretary of Health and Human Services, part A: executive summary.   Nutr Rev. 2009;67(2):114-120. doi:10.1111/j.1753-4887.2008.00136.xPubMedGoogle Scholar
20.
Al Khalifah  RA, Florez  ID, Dennis  B, Thabane  L, Bassilious  E.  Metformin or oral contraceptives for adolescents with polycystic ovarian syndrome: a meta-analysis.   Pediatrics. 2016;137(5):e20154089. doi:10.1542/peds.2015-4089 PubMedGoogle Scholar
21.
Wei  S, Schmidt  MD, Dwyer  T, Norman  RJ, Venn  AJ.  Obesity and menstrual irregularity: associations with SHBG, testosterone, and insulin.   Obesity (Silver Spring). 2009;17(5):1070-1076. doi:10.1038/oby.2008.641 PubMedGoogle Scholar
22.
Langenberg  C, Sharp  SJ, Schulze  MB,  et al; InterAct Consortium.  Long-term risk of incident type 2 diabetes and measures of overall and regional obesity: the EPIC-InterAct case-cohort study.   PLoS Med. 2012;9(6):e1001230. doi:10.1371/journal.pmed.1001230 PubMedGoogle Scholar
23.
Knol  MJ, VanderWeele  TJ.  Recommendations for presenting analyses of effect modification and interaction.   Int J Epidemiol. 2012;41(2):514-520. doi:10.1093/ije/dyr218 PubMedGoogle Scholar
24.
VanderWeele  TJ, Tchetgen Tchetgen  EJ.  Attributing effects to interactions.   Epidemiology. 2014;25(5):711-722. doi:10.1097/EDE.0000000000000096 PubMedGoogle Scholar
25.
Dunaif  A.  Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis.   Endocr Rev. 1997;18(6):774-800. doi:10.1210/edrv.18.6.0318PubMedGoogle Scholar
26.
Plymate  SR, Matej  LA, Jones  RE, Friedl  KE.  Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin.   J Clin Endocrinol Metab. 1988;67(3):460-464. doi:10.1210/jcem-67-3-460 PubMedGoogle Scholar
27.
Shanik  MH, Xu  Y, Skrha  J, Dankner  R, Zick  Y, Roth  J.  Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse?   Diabetes Care. 2008;31(suppl 2):S262-S268. doi:10.2337/dc08-s264 PubMedGoogle Scholar
28.
Alvergne  A, Högqvist Tabor  V.  Is female health cyclical? evolutionary perspectives on menstruation.   Trends Ecol Evol. 2018;33(6):399-414. doi:10.1016/j.tree.2018.03.006 PubMedGoogle Scholar
29.
Murri  M, Luque-Ramírez  M, Insenser  M, Ojeda-Ojeda  M, Escobar-Morreale  HF.  Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a systematic review and meta-analysis.   Hum Reprod Update. 2013;19(3):268-288. doi:10.1093/humupd/dms059 PubMedGoogle Scholar
30.
Brower  M, Brennan  K, Pall  M, Azziz  R.  The severity of menstrual dysfunction as a predictor of insulin resistance in PCOS.   J Clin Endocrinol Metab. 2013;98(12):E1967-E1971. doi:10.1210/jc.2013-2815 PubMedGoogle Scholar
31.
Dishi  M, Enquobahrie  DA, Abetew  DF, Qiu  C, Rudra  CB, Williams  MA.  Age at menarche, menstrual cycle characteristics and risk of gestational diabetes.   Diabetes Res Clin Pract. 2011;93(3):437-442. doi:10.1016/j.diabres.2011.07.001 PubMedGoogle Scholar
32.
Kim  SW, Jeon  JH, Lee  WK,  et al.  Long-term effects of oral contraceptives on the prevalence of diabetes in post-menopausal women: 2007-2012 KNHANES.   Endocrine. 2016;53(3):816-822. doi:10.1007/s12020-016-0972-z PubMedGoogle Scholar
33.
Hedderson  MM, Ferrara  A, Williams  MA, Holt  VL, Weiss  NS.  Androgenicity of progestins in hormonal contraceptives and the risk of gestational diabetes mellitus.   Diabetes Care. 2007;30(5):1062-1068. doi:10.2337/dc06-2227 PubMedGoogle Scholar
34.
Wang  YX, Arvizu  M, Rich-Edwards  JW,  et al.  Menstrual cycle regularity and length across the reproductive lifespan and risk of premature mortality: prospective cohort study.   BMJ. 2020;371:m3464. doi:10.1136/bmj.m3464 PubMedGoogle Scholar
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    1 Comment for this article
    EXPAND ALL
    Consequences are not causes. Irregular cycles and Insulin Resistance are consequences of abnormal weight gain.
    Pandiyan Natarajan, MBBS, DGO, MD, MNAMS, FARM | Professor and Head of the department of Andrology and Reproductive Medicine, Chettinad Super Speciality Hospital, Rajiv Gandhi Salai, Kelambakkam, Chennai, Tamil Nadu, India, 603103
    Overweight and obesity are well established causes of insulin resistance, PCOS, type 2 diabetes mellitus and the metabolic syndrome. Ninety percent of patients with type 2 diabetes are obese or overweight. In the United States, more than half of the patients with PCOS are either overweight or obese.(1) Normal weight and thin individuals may also develop these conditions if they have had significant weight gain since puberty or in adulthood, even if their weight is still in the so called ‘normal BMI range.’ The natural history of PCOS is a progression from anovulation, i0rregular cycles to the classical stigmata of PCOS. Weight gain is the precipitating factor regardless of BMI.(2) Any post pubertal weight gain, other than due to pregnancy or body building, may lead to PCOS. When growth in the Y axis has stopped, growth in the X axis (weight gain) will lead to consequences. Irregular cycle is one of the earliest sign/symptom of abnormal weight gain. Oligo ovulation or anovulation and consequent irregular cycles are the outcome.

    We now believe that ‘abnormal weight gain’ is the primary pathology leading to PCOS and the other cascade of events. (2, 3). The other events like insulin resistance, menstrual irregularities, PCOS and metabolic syndromes are the consequences of this ‘abnormal weight gain, and likely not the cause of the ensuing clinical pictures.

    It may be a leap implicate menstrual irregularities in the causation of type 2 diabetes. Both conditions have a common origin- abnormal weight gain- and are unlike to be causally related.

    References:
    1) Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO 2004 The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89:2745–2749

    2) Puvithra T and Pandiyan N Is Weight Gain the Precipitating Factor for Polycystic Ovarian Syndrome? A Hypothesis Based on a Retrospective Study. Chettinad Health City Medical Journal 2015; 4(3): 120 - 124.

    3) Puvithra.T and N.Pandiyan Polycystic Ovary Syndrome is an Epiphenomenon - An Opinion Chettinad Health City Medical Journal 2016; 5(3): 106 - 107
    CONFLICT OF INTEREST: None Reported
    READ MORE
    Original Investigation
    Diabetes and Endocrinology
    December 21, 2020

    Associations of Menstrual Cycle Characteristics Across the Reproductive Life Span and Lifestyle Factors With Risk of Type 2 Diabetes

    Author Affiliations
    • 1Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts
    • 2Department of Epidemiology and Biostatistics, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, PR China
    • 3Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts
    • 4Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
    • 5Division of Preventive Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
    • 6Department of Obstetrics and Gynecology and Reproductive Biology, College of Human Medicine, Michigan State University, Grand Rapids
    JAMA Netw Open. 2020;3(12):e2027928. doi:10.1001/jamanetworkopen.2020.27928
    Key Points

    Question  Are irregular or long menstrual cycles and unhealthy lifestyle factors jointly associated with type 2 diabetes?

    Findings  In this prospective cohort study of 75 546 women, irregular and long menstrual cycles across the reproductive life span were associated with a greater risk of type 2 diabetes. These associations were stronger among women with overweight or obesity, low-quality diet, and low levels of physical activity.

    Meaning  These findings suggest that menstrual cycle characteristics may serve as an early sign of the long-term risk of developing type 2 diabetes and that lifestyle interventions may be a useful strategy to reduce the risk of type 2 diabetes among women with menstrual cycle dysfunction.

    Abstract

    Importance  Menstrual cycle dysfunction is associated with insulin resistance, a key feature early in the pathogenesis of type 2 diabetes. However, the evidence linking irregular and long menstrual cycles with type 2 diabetes is scarce and inconsistent.

    Objectives  To evaluate the associations between menstrual cycle characteristics at different points throughout a woman’s reproductive life span and risk of type 2 diabetes and the extent to which this association is modified by lifestyle factors.

    Design, Setting, and Participants  This prospective cohort study included 75 546 premenopausal US female nurses participating in the Nurses’ Health Study II from 1993 to June 30, 2017. Data analysis was performed from February 1 to December 30, 2019.

    Exposures  Self-reported usual length and regularity of menstrual cycles at the age ranges of 14 to 17 years, 18 to 22 years, and 29 to 46 years.

    Main Outcomes and Measures  Incident type 2 diabetes identified through self-report and confirmed by validated supplemental questionnaires.

    Results  Among the 75 546 women in the study at baseline, the mean (SD) age was 37.9 (4.6) years (range, 29.0-46.0 years). A total of 5608 participants (7.4%) had documented new cases of type 2 diabetes during 1 639 485 person-years of follow-up. After adjustment for potential confounders, women reporting always having irregular menstrual cycles between the age ranges of 14 to 17 years, 18 to 22 years, and 29 to 46 years were, respectively, 32% (95% CI, 22%-44%), 41% (95% CI, 23%-62%), and 66% (95% CI, 49%-84%) more likely to develop type 2 diabetes than women reporting very regular cycles (within 3-4 days of expected period) in the same age range. Similarly, women reporting a usual cycle length of 40 days or more between the age ranges of 18 to 22 years and 29 to 46 years were, respectively, 37% (95% CI, 19%-57%) and 50% (95% CI, 36%-65%) more likely to develop type 2 diabetes during follow-up compared with women reporting a usual cycle length of 26 to 31 days in the same age ranges. These associations appeared to be stronger among women with overweight or obesity, a low-quality diet, and low levels of physical activity. The relative excess risk of type 2 diabetes due to the interaction between irregular and long menstrual cycles and the overall unhealthy lifestyle score was 0.73 (95% CI, 0.57-0.89) and 0.68 (95% CI, 0.54-0.83), respectively.

    Conclusions and Relevance  In this cohort study of US female nurses participating in the Nurses’ Health Study II, irregular and long menstrual cycles throughout life were associated with a greater risk of type 2 diabetes, particularly among women with overweight or obesity, a low-quality diet, and low levels of physical activity.

    ×